Maxim analyst Jason McCarthy initiated coverage of Aprea Therapeutics with a Buy rating and $16 price target. Aprea is an emerging player in drug development with its pipeline of next-generation molecules and discovery platform aimed at leveraging the concept of synthetic lethality in targeting the DNA damage response pathways in cancer cells, the analyst tells investors in a research note. The analyst models commercialization of ATRN-119 for advanced/metastatic ovarian cancer in 2028 and for advanced metastatic breast cancer in 2030.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on APRE:
- Aprea Therapeutics regains compliance with Nasdaq minimum bid rule
- Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
- Aprea Therapeutics Announces Closing of $5.5 Million Underwritten Public Offering of Common Stock
- Aprea Therapeutics 1.05M share Spot Secondary priced at $5.25
- Aprea Therapeutics Announces Pricing of $5.5 Million Underwritten Public Offering of Common Stock
